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Introduction {#sec1}
============

Neural stem cell culture systems could potentially advance our understanding of human brain development and disease ([@bib20]). The capture of self-renewing neural progenitor cells *in vitro* provides scalable cell populations for biochemical or genetic studies. Importantly, neural stem cells can be genetically manipulated or differentiated in a controlled environment and therefore allow functional studies that would not be possible in human brain.

It has been postulated that brain tumors could develop from neural progenitors that deviate from their developmental pathway ([@bib74]). *Ex vivo* culture of cell populations that are susceptible to tumorigenesis may provide insight into how neural progenitors become malignant ([@bib45], [@bib70]). A specific subpopulation of long-term neuroepithelial stem (NES) cells can be captured from human pluripotent stem-cell-derived neural rosettes and propagated long-term in culture ([@bib18], [@bib43]). These cells maintain neuroepithelial properties in culture; the expression of rosette-stage-specific markers such as *SOX1*, *PLZF1*, *DACH1*, and *MMNR1*; and high neurogenic potency. They exhibit hindbrain regional identity, including expression of *GBX2* and *KROX20*, and maintain responsiveness to ventral and dorsal cell fate cues in a similar way to the developing neuroepithelium ([@bib43]). Furthermore, stem cells expanded directly from the rostral hindbrain neuroepithelium of 5- to 6-week human fetuses show characteristics similar to human induced pluripotent stem cell (iPSC)-derived NES cells, suggesting that these cells are indeed representative of neuroepithelial progenitors in the cerebellar primordium ([@bib87]). NES cells maintain potency for the cerebellar lineage both *in vitro* and following orthotopic transplantation, including differentiation to cerebellar granule neural precursor (GNP) cells ([@bib87]). Moreover, they are scalable, genetically stable after long-term passages, and amenable to gene editing and drug screening platforms ([@bib11], [@bib18], [@bib59]). However, the tumorigenic potential of hindbrain NES cells in the context of tumor-predisposing mutations has not yet been explored.

The rostral hindbrain neuroepithelium (rhombomere 1) comprises two major germinal zones that generate cerebellar cells. The ventricular neuroepithelium lies at the roof of the developing fourth ventricle and harbors precursors of GABAergic Purkinje neurons, Golgi and Lugaro interneurons. By contrast, the upper rhombic lip is located at the interface between rhombomere 1 and the roof plate and generates all the glutamatergic cells of the cerebellum, including cerebellar GNP cells ([@bib61], [@bib91], [@bib94]). GNP cells are thought to be precursors of medulloblastoma, a common malignant brain tumor of childhood and young adults (reviewed in [@bib65]). GNP cells proliferate extensively in the external granule layer (EGL) of the post-natal brain in response to Sonic Hedgehog (SHH) ligand, a major regulator of cerebellar development ([@bib10], [@bib93]). SHH signaling occurs following interaction of the SHH ligand with PTCH1 receptor, which de-represses Smoothened (SMO) and activates downstream target genes ([@bib28]). Aberrations in SHH signaling are well described in medulloblastoma. In particular, inactivating mutations in the *PTCH1* gene leading to constitutive activity of SMO are found in ∼25% of medulloblastoma ([@bib7], [@bib64]).

A germline mutation in *PTCH1* is responsible for an autosomal-dominant, tumor-prone condition, Gorlin syndrome (also known as nevoid basal cell carcinoma syndrome) ([@bib25], [@bib35]). Patients with this syndrome develop multiple basal cell carcinomas of the skin and are also predisposed to medulloblastoma. Analogously, ∼15% of *Ptch1*^*+/−*^ transgenic mice also develop medulloblastoma ([@bib22]). Pre-neoplastic lesions can be identified in the EGL of over 50% of these mice in early post-natal life ([@bib66]), suggesting that the GNP cell population is particularly susceptible to the effects of SHH overactivity. Conditional knockout of *Ptch1* in GNP cells led to the formation of medulloblastoma in all mice by 3 months of age, confirming that GNP cells are susceptible to oncogenic transformation in the context of SHH overactivity ([@bib97]). Interestingly, *Ptch1* deletion in precursors of GNP cells located in the ventricular zone of the dorsal hindbrain also initiated medulloblastoma ([@bib51]). Similar results have been observed with overexpression of *Smo* in multipotent cerebellar progenitors ([@bib77]).

We hypothesized that NES cells, as progenitors of the cerebellar primordium with competence for generation of GNP cells, could provide a human model system to study medulloblastoma initiation and development. We tested this idea, first by transducing NES cells with *MYCN* and second by deriving NES cells from patients with Gorlin syndrome, bearing germline mutations in *PTCH1*, and in each case performing orthotopic transplantation in mice. We then explored the opportunity for functional validation of candidate drivers of medulloblastoma that co-occur with *PTCH1* mutations.

Results {#sec2}
=======

*MYCN* Drives Transformation of Normal Human iPSC-Derived NES Cells to SHH Medulloblastoma {#sec2.1}
------------------------------------------------------------------------------------------

We first asked whether neuroepithelial stem (NES) cells can be transformed into brain-tumor-initiating cells by a known driver of medulloblastoma. Amplification of *MYCN* correlates with high-risk SHH medulloblastoma, and MYCN can drive medulloblastoma in germline and non-germline genetically engineered mouse models (GEMMs) ([@bib85], [@bib86]). Human iPSCs derived from keratinocytes of a karyotypically normal adult (WTC10) using episomes ([@bib27]) were converted into NES cells as described previously ([@bib18], [@bib43]) and retained a normal karyotype. Subsequently, NES cells were transduced with FLAG-tagged *MYCN* ([Figures 1](#fig1){ref-type="fig"}A and 1B), leading to increased proliferation and a higher proportion of cells in S phase compared to NES cells transduced with empty vector ([Figures 1](#fig1){ref-type="fig"}C and 1D). We implanted empty vector control and *MYCN* NES cells orthotopically in immunocompromised mice. *MYCN* NES cells generated tumors between 42 and 57 days post-injection ([Figure 1](#fig1){ref-type="fig"}E). Tumors extracted from cerebellum were transplantable, indicating malignancy. Histological analysis revealed an embryonal neoplasm with anaplastic features and immunopositive for synaptophysin, a neuronal marker characteristic of human medulloblastoma, and for FLAG-tagged MYCN ([Figures 1](#fig1){ref-type="fig"}F, [S1](#mmc1){ref-type="supplementary-material"}A, and S1C). Although human pluripotent stem cells have been described to spontaneously acquire dominant-negative p53 mutations leading to basal expression of p53 ([@bib60]), p53 was undetectable by immunohistochemical analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}B and S1C).Figure 1*MYCN* Drives Transformation of NES Cells to Medulloblastoma(A) Schematic showing differentiation of iPSCs to NES cells, transduction with FLAG-MYCN, and orthotopic implantation into mice.(B) Western blot showing misexpressed MYCN in normal WTC10 NES cells.(C) Empty vector and *MYCN* NES cells were treated with 5-ethynyl-2′-deoxyuridine (EdU) for 1 h and analyzed via flow cytometry. *MYCN* NES cells show increased EdU incorporation and S-phase fraction. Data are presented as mean ± SEM; ^∗^p \< 0.05 (t test).(D) CyQuant Direct cell proliferation analysis showing increased proliferation in *MYCN* NES cells. Data are presented as mean ± SEM; ^∗^p \< 0.05 (t test).(E) Kaplan-Meier survival curve of mice injected with empty vector and *MYCN* NES cells (n = 4). p = 0.004 (log-rank test).(F) (Left) Low magnification (50×) of H&E staining of WTC10 *MYCN* tumors showing implanted *MYCN* NES cells expanding and distorting the mouse cerebellum and invading down Virchow-Robin spaces (arrow). (Middle) High magnification (400×) of H&E staining revealing anaplastic features including frequent mitoses (arrows), cell-cell wrapping (black arrowhead), prominent nuclei (red arrowhead), and karyorrhexis (red arrow) characteristic of large cell and/or anaplastic medulloblastoma. (Right) Immunohistochemical staining for synaptophysin (SYP) highlighting neuroblastic pseudorosettes. Scale bars represent 200 μm for 50× images and 20 μm for 400× images.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"}, [S4](#mmc5){ref-type="supplementary-material"}, and [S6](#mmc7){ref-type="supplementary-material"}.

Next, we compared molecular characteristics of tumors derived from *MYCN* NES cells (referred as WTC10 *MYCN* tumors) with human medulloblastoma patient tumors. GEMMs have been previously reported to lack DNA methylation changes found in human medulloblastoma ([@bib14]). Using Illumina methylation arrays, we identified 66 differentially methylated regions (DMRs) comparing human patient SHH medulloblastoma (amplified for *MYCN*) to normal cerebellum, whereas 130 DMRs were identified in WTC10 *MYCN* tumors (data not shown). The majority of these DMRs were hypermethylated in both sets of tumors. WTC10 *MYCN* tumors showed similar focal changes in methylation in regions that overlapped 41% (27/66) of the DMRs found in medulloblastoma tumors from patients ([Figure 2](#fig2){ref-type="fig"}A).Figure 2WTC10 *MYCN* Tumors Align with SHH Medulloblastoma(A) Genomic DNA was extracted from WTC10 *MYCN* tumors and analyzed via Illumina methylation arrays. Differentially methylated regions (DMRs) relative to normal human cerebellum were identified in SHH medulloblastoma (MB) from patients with *MYCN-*amplified tumors (top) and compared with WTC10 *MYCN* tumors (bottom). The complexity of overall methylation differences (comparing normal cerebellum with each tumor type) was similar in WTC10 *MYCN* tumors and human medulloblastoma tumors, contrasting a published report comparing GEMM models (including MYCN-driven GEMMs) with human tumors ([@bib14]).(B) Comparing transcriptomes of WTC10 *MYCN* tumors with other pediatric brain tumors using principal component analysis (PCA) showed WTC10 *MYCN* tumors aligned best with medulloblastoma.(C and D) Comparison of transcriptomes of human WTC10 *MYCN* tumors and murine MYCN-driven GEMM tumors (GTML, [@bib85]) with four major subgroups of medulloblastoma using (C) PCA and (D) support vector machine (SVM) classification. WTC10 *MYCN* tumors aligned with SHH subgroup, whereas GTML aligned with group 3 medulloblastoma. For SVM, colors indicate class prediction probabilities (blue, low; red, high), and asterisks denote the predicted class.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"}, [S4](#mmc5){ref-type="supplementary-material"}, and [S6](#mmc7){ref-type="supplementary-material"}.

We then performed RNA sequencing (RNA-seq) and differential gene expression analysis of WTC10 *MYCN* tumors and parental NES cells. Among the 10 most upregulated genes in WTC10 *MYCN* tumors compared to NES cells ([Table S1](#mmc2){ref-type="supplementary-material"}), genes previously linked to cancer progression and malignancy include *AVP*, *BARHL1*, *HELT*, and *LMX1A* ([@bib71], [@bib83], [@bib84], [@bib90]). Global transcriptome analysis also indicated that WTC10 *MYCN* tumors resembled medulloblastoma more closely than normal brain and other pediatric brain tumors (glioblastoma, pilocytic astrocytoma, and ependymoma; [Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A).

Previously, we generated a GEMM of medulloblastoma driven by misexpression of *MYCN* (referred as GTML) ([@bib85]). The transcriptome of GTML GEMM tumors aligned with group 3 medulloblastoma, a subgroup in which patient tumors commonly amplify *CMYC* and only rarely amplify *MYCN* ([@bib64]). In contrast, WTC10 *MYCN* tumors clustered with SHH medulloblastoma ([Figures 2](#fig2){ref-type="fig"}C, 2D, and [S2](#mmc1){ref-type="supplementary-material"}B). In support of WTC10 *MYCN* tumors representing SHH medulloblastoma, WTC10 *MYCN* tumors, compared to parental NES cells, showed increased expression of *ATOH1*, a marker of GNP cells, a cell of origin for SHH medulloblastoma ([Table S1](#mmc2){ref-type="supplementary-material"}). Thus, the human stem cell-based model of medulloblastoma showed greater similarity to the relevant primary tumor, as compared to a tumor created in mouse cells using the same oncogenic driver.

Human iPSCs from Patients with Gorlin Syndrome {#sec2.2}
----------------------------------------------

Next, we explored if NES cells with mutant *PTCH1* would generate medulloblastoma. Mutation of *PTCH1* occurs frequently in SHH medulloblastoma ([@bib7], [@bib44], [@bib64]), and *Ptch1*^+/−^ drives medulloblastoma in mice ([@bib22]). To determine whether *PTCH1* loss also generates medulloblastoma in a human stem cell system, we isolated keratinocytes from a healthy control (KTM1, referred as control) and from two different patients with Gorlin syndrome (KAS537 and KAS573 referred as Gorlin 1 and Gorlin 2, respectively; [Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), both of whom were predisposed to medulloblastoma due to heterozygous germline mutations in *PTCH1* ([@bib9], [@bib25], [@bib35], [@bib95]). Keratinocytes from both Gorlin patients had distinct nucleotide insertions within an exon of one *PTCH1* allele (1762dupG for Gorlin 1 and 1925dupC for Gorlin 2; [Figure S3](#mmc1){ref-type="supplementary-material"}B), resulting in a frameshift and premature STOP codon (V588G_fsX39 for Gorlin 1, P643T_fsX11 for Gorlin 2, [Figure S3](#mmc1){ref-type="supplementary-material"}B). We used Sendai virus to generate iPSCs, confirmed by expression of pluripotent markers NANOG, OCT4, and SOX2 ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). The Sendai virus antigen could not be detected by immunofluorescence in the clonal iPSC lines after five passages (data not shown). When differentiated to embryoid bodies, both Gorlin iPSC lines showed expression of markers for neuroectoderm (SOX1 and TUJ1), mesoderm (TBRA), and endoderm (SOX17) ([Figure S3](#mmc1){ref-type="supplementary-material"}E). We next implanted Gorlin iPSCs into the kidney capsule of immunocompromised mice and obtained teratomas expressing markers of all three germ layers ([Figure S3](#mmc1){ref-type="supplementary-material"}F). These results validated that Gorlin iPSC showed pluripotency.

Gorlin NES Cells Display Neural Characteristics with Enhanced Proliferation and SHH Signaling {#sec2.3}
---------------------------------------------------------------------------------------------

We generated NES cells from Gorlin iPSC ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Similar to control NES cells, both Gorlin NES cells expressed neural markers (NESTIN, SOX2, SOX1, and PAX6) while suppressing pluripotency markers (OCT4 and NANOG; [Figure 3](#fig3){ref-type="fig"}A). Importantly, NES cells from both Gorlin iPSC lines retained a normal karyotype ([Figure 3](#fig3){ref-type="fig"}B). Cell-cycle profiles were not different between normal and Gorlin NES cells ([Figure 3](#fig3){ref-type="fig"}C); however, both Gorlin lines showed a proliferative advantage in the CyQuant Direct cell proliferation assay as compared to control ([Figure 3](#fig3){ref-type="fig"}D). Gorlin NES cells maintained expression of neuroepithelial stage (*PLZF1* and *MMNR1*) and hindbrain (*GBX2*) markers, similar to NES cells derived from fetal hindbrain ([@bib87]) ([Figure S3](#mmc1){ref-type="supplementary-material"}H).Figure 3Gorlin NES Cells Display Neural Characteristics with Enhanced Proliferation and SHH Signaling(A) Similar to Control NES cells, Gorlin NES cells expressed NES cell-related markers (NESTIN, SOX1, SOX2, and PAX6), but not pluripotency markers (OCT4 and NANOG). Scale bars represent 20 μm.(B) Normal karyotypes for both Gorlin NES lines scored from 20 spreads each.(C) Control and Gorlin NES cells were treated with EdU for 1 h and analyzed by flow cytometry. No significant differences were seen in cell-cycle profile of each cell line. Data are presented as mean ± SEM.(D) CyQuant Direct cell proliferation assay of control and Gorlin NES cells show both Gorlin NES cell lines grew faster than control NES cells. Data are presented as mean ± SEM. ^∗^p \< 0.05 (t test).(E) RT-qPCR quantitation of *GLI1* mRNA expression in Control and Gorlin NES cells.(F) RT-qPCR quantitation of *GLI1* mRNA expression in Control and Gorlin NES cells untreated or treated with SHH ligand (800 ng/mL) for 2 days. Gorlin 1 NES cells show modestly increased sensitivity to stimulation with SHH ligand compared with control NES cells. Data are presented as mean ± SEM.See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc3){ref-type="supplementary-material"}.

Despite heterozygosity for *PTCH1*, Gorlin NES cells did not show a basal increase in abundance of the SHH downstream target *GLI1* ([Figure 3](#fig3){ref-type="fig"}E). In response to stimulation with SHH ligand, one of two Gorlin NES cells (Gorlin 1) showed a modest increased abundance of *GLI1* mRNA compared to control NES cells ([Figure 3](#fig3){ref-type="fig"}F). These data show that Gorlin NES cells had a modest growth advantage and may be more sensitive to SHH ligand stimulation compared to control NES cells.

Gorlin NES Cells Generate SHH Medulloblastoma *In Vivo* {#sec2.4}
-------------------------------------------------------

We investigated whether Gorlin NES cells could generate tumors *in vivo*. Control NES cells and NES cells from both Gorlin patients were injected orthotopically into hindbrains of immunocompromised mice ([Figure 4](#fig4){ref-type="fig"}A). Mice developed signs of tumor between 102 and 206 days for Gorlin 1 and 254 and 360 days for Gorlin 2 NES cells ([Figure 4](#fig4){ref-type="fig"}B). Luminescence imaging revealed that both Gorlin 1 and Gorlin 2 NES cells xenografted equally well, suggesting the difference in penetrance and latency was due to the proliferative advantage of Gorlin 1 NES cells (data not shown; [Figure 3](#fig3){ref-type="fig"}D). To further investigate differences between Gorlin 1 and Gorlin 2 NES cells, we performed RNA-seq analysis on both Gorlin NES cell lines. Among the 10 most upregulated genes in Gorlin 1 NES cells compared to Gorlin 2 NES cells, the genes linked to tumor growth and malignancy that might contribute to the difference in latency included *CYP24A1*, *FZD10*, and *HIST1H3C* ([@bib12], [@bib80], [@bib89]) ([Table S2](#mmc3){ref-type="supplementary-material"}). Another possible explanation for the increased penetrance from Gorlin 1 NES cells is due to significantly reduced expression of *PTCH2* (\>4-fold) in Gorlin 1 NES cells compared to Gorlin 2 NES cells ([Table S2](#mmc3){ref-type="supplementary-material"}). Loss of one or both copies of *Ptch2* has been shown to accelerate tumorigenesis in *Ptch1*^+/−^ mice ([@bib47]).Figure 4Gorlin NES Cells Generate SHH Medulloblastoma *In Vivo*(A) Schematic of differentiation of control and Gorlin iPSC toward NES cells, implantation into hindbrains of immunocompromised mice, and generation of tumors.(B) Kaplan-Meier survival curve of mice (n = 10) implanted with each cell line. p \< 0.0001 (log-rank test).(C) Gorlin tumors showed a hypercellular embryonal neoplasm with indistinct cell borders, frequent mitoses (arrows), prominent nuclei (red arrowhead), karyorrhexis (red arrow), and synaptophysin (SYP) positivity. Scale bars represent 20 μm.(D) Comparison of transcriptomes of Gorlin 1 tumors with other pediatric brain tumors using (top) PCA and (bottom) SVM classification. Gorlin 1 tumors align with medulloblastoma.(E) Comparison of transcriptomes of Gorlin 1 tumors with four major subgroups of medulloblastoma using (top) PCA and (bottom) SVM classification. Gorlin 1 tumors aligned with SHH subgroup. For SVM, colors indicate class prediction probabilities (blue, low; red, high), and asterisks denote the predicted class.See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"} and [Tables S2](#mmc3){ref-type="supplementary-material"}, [S5](#mmc6){ref-type="supplementary-material"}, and [S7](#mmc8){ref-type="supplementary-material"}.

H&E staining revealed an embryonal neoplasm with mild to moderate nuclear pleomorphism and frequent mitoses characteristic of medulloblastoma ([@bib57]) ([Figure 4](#fig4){ref-type="fig"}C). Immunohistochemistry showed abundant expression of synaptophysin ([Figure 4](#fig4){ref-type="fig"}C). RNA-seq analysis aligned Gorlin 1 tumors with human SHH medulloblastoma as compared to other subtypes of medulloblastoma and other types of pediatric brain tumors ([Figures 4](#fig4){ref-type="fig"}D, 4E, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B). Similar to the WTC10 *MYCN* tumors, Gorlin 1 tumors showed elevated expression of the GNP cell marker *ATOH1* compared to the Gorlin 1 NES cells ([Table S2](#mmc3){ref-type="supplementary-material"}). Thus, Gorlin tumors resembled SHH medulloblastoma.

Human NES Cells Are Not Committed to the GNP Lineage {#sec2.5}
----------------------------------------------------

Since the WTC10 *MYCN* and Gorlin tumors both aligned with SHH medulloblastoma, we sought to determine whether NES cells were committed or "primed" to be in a GNP-like state. We first compared the transcriptomes of WTC10 NES cells, Gorlin 1 NES cells, and Gorlin 2 NES cells with mouse GNPs ([@bib6]). Hierarchical clustering analysis showed the transcriptome profiles of all three NES cells were distinct from GNPs ([Figure 5](#fig5){ref-type="fig"}A). Next, for each NES cell line, we either maintained undifferentiated, differentiated spontaneously, or differentiated directly with Wnt3a and GDF7, factors known to stimulate expression of the GNP marker *ATOH1* ([@bib87]). Upon stimulation of NES cells with Wnt3a and GDF7, analysis by RT-qPCR revealed a substantial increase in expression of *ATOH1* compared to spontaneously differentiated or undifferentiated NES cells ([Figure 5](#fig5){ref-type="fig"}B). Thus, while NES cells clearly have the capacity to generate GNPs, they are not committed to that lineage.Figure 5Human NES Cells Are Not Committed to the GNP Lineage(A) Hierarchical clustering heatmap showing human WTC10 NES and both Gorlin NES cells have transcriptome profiles distinct from mouse GNPs ([@bib6]).(B) WTC10 NES cells and both Gorlin NES cells were differentiated spontaneously or stimulated with Wnt3a (20 ng/mL) and GDF7 (100 ng/mL) for 2 days. Analysis by RT-qPCR shows stimulation with Wnt3a and GDF7 substantially increased GNP marker *ATOH1* compared to spontaneously differentiated cells and parental NES cells. Data are presented as mean ± SEM.

Mutation of *DDX3X* and *GSE1*, but Not *KDM3B*, Accelerates Tumorigenesis in Gorlin 1 NES Cells {#sec2.6}
------------------------------------------------------------------------------------------------

We then asked whether the Gorlin NES cell model could be used to test candidate genetic drivers. Sporadic mutation of *PTCH1* occurs mainly in adult medulloblastoma ([@bib7], [@bib44], [@bib64]). Among these adult patients, co-occurring mutations are found commonly in candidate genes, including *DDX3X*, an RNA helicase; genetic suppressor element 1 (*GSE1*), a coiled-coiled protein known to interact with HDAC1 ([@bib5]); and lysine demethylase 3B (*KDM3B*), a demethylase with both tumor-suppressive and tumor-promoting effects ([@bib40], [@bib96]). Whereas *DDX3X* mutations are always missense, mutations in *GSE1* and *KDM3B* are typically frameshifts, nonsense, or deletions ([@bib36], [@bib44], [@bib63], [@bib72], [@bib75]).

Mutations in *DDX3X* typically occur within its two RNA helicase domains. In SHH medulloblastoma, the most frequent mutations at the N-terminal and C-terminal helicase domains are *DDX3X*^*R351W*^ and *DDX3X*^*R534S*^, respectively ([@bib44], [@bib64]). To evaluate effects of these mutations, we misexpressed FLAG-tagged *DDX3X*^*WT*^, *DDX3X*^*R351W*^, or *DDX3X*^*R534S*^ at similar levels in Gorlin 1 NES cells ([Figure 6](#fig6){ref-type="fig"}A). While NES cells with mutant *DDX3X* did not exhibit altered proliferation *in vitro* ([Figures 6](#fig6){ref-type="fig"}B and 6C), mutant *DDX3X* accelerated tumorigenesis *in vivo* ([Figure 6](#fig6){ref-type="fig"}D). Principal component analysis, support vector machine, and hierarchical clustering show the *DDX3X* mutant tumors aligned with SHH medulloblastoma ([Figures 6](#fig6){ref-type="fig"}E, 6F, and [S5](#mmc1){ref-type="supplementary-material"}A). Among the 10 most upregulated genes in Gorlin 1 *DDX3X*^*R351W*^ tumors (compared to Gorlin 1 tumors), genes previously implicated in tumor growth and malignancy include *HOXA3*, *HOXB3*, *KRT6A*, and *S100A9* ([@bib8], [@bib34], [@bib53], [@bib98]) ([Table S3](#mmc4){ref-type="supplementary-material"}). Among the 10 most upregulated genes in Gorlin 1 *DDX3X*^*R534S*^ tumors (compared to Gorlin 1 tumors), genes previously linked with cancer include *DDX43*, *KRT7*, *HOXB3*, and *NNAT* ([@bib3], [@bib33], [@bib55], [@bib81]) ([Table S3](#mmc4){ref-type="supplementary-material"}). These experiments validate *DDX3X* mutations as drivers of SHH medulloblastoma.Figure 6Mutation of *DDX3X* in Gorlin 1 NES Cells Accelerates Tumorigenesis(A) Western blot of FLAG (DDX3X) expression in Gorlin 1 NES cells with *DDX3X*^*WT*^, *DDX3X*^*R351W*^, or *DDX3X*^*R534S*^*.*(B) EdU assay of Gorlin 1 NES cells with *DDX3X* mutants. Data are presented as mean ± SEM.(C) CyQuant Direct cell proliferation assay of Gorlin 1 NES cells with *DDX3X* mutants. Data are presented as mean ± SEM.(D) Kaplan-Meier survival curve showing accelerated tumorigenesis in mice implanted with NES cells harboring *DDX3X* mutations (n = 5). p = 0.029 (log-rank test).(E and F) Comparison of transcriptomes of three *DDX3X*^*R351W*^ and three *DDX3X*^*R534S*^ tumors with the four major subgroups of medulloblastoma using (E) PCA and (F) SVM classification. PCA and SVM classification show all six *DDX3X* mutant tumors subgrouped with SHH medulloblastoma. For SVM, colors indicate class prediction probabilities (blue, low; red, high), and asterisks denote the predicted class.See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc4){ref-type="supplementary-material"}.

Expression of GSE1 and KDM3B correlates inversely with survival in patients with medulloblastoma ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Therefore, we created lentiviral CRISPR/Cas9 plasmids targeting *GSE1* or *KDM3B* to generate indels in each gene ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Transduction of Gorlin 1 NES cells followed by selection with puromycin resulted in cells with frameshift mutations in both genes, as well as decreased levels of GSE1 and KDM3B proteins ([Figure 7](#fig7){ref-type="fig"}A). Amplicon sequencing of the target regions (50,000 reads each) revealed mutation frequencies of 96.7% (69.8% for frameshift) for *KDM3B* and 99.2% (87.9% for frameshift) for *GSE1* ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). Neither loss of *GSE1* nor loss of KDM3B significantly affected proliferation in Gorlin 1 NES cells ([Figures 7](#fig7){ref-type="fig"}B and 7C). Next, we tested whether either of these mutations influenced tumorigenesis *in vivo*. We injected each Gorlin NES cell line (transduced with Ctrl single guide RNA \[sgRNA\], GSE1 sgRNA, or KDM3B sgRNA) into hindbrains of immunocompromised mice. Targeting of *GSE1*, but not *KDM3B*, significantly decreased the latency of Gorlin 1 tumors ([Figure 7](#fig7){ref-type="fig"}D). RNA-seq analysis of three *GSE1* mutant tumors (referred as *GSE1*^−/−^ tumors) shows that the tumors again clustered with the SHH subgroup ([Figures 7](#fig7){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}B). Among the 10 most upregulated genes in *GSE1*^−/−^ tumors compared to Gorlin 1 tumors, genes associated with cancer include *CTSG*, *ELANE*, *HIST1H3C*, *NNAT*, *PEG3*, *PRTN3*, and *RNLS* ([@bib2], [@bib12], [@bib24], [@bib30], [@bib32], [@bib67], [@bib81]) ([Table S3](#mmc4){ref-type="supplementary-material"}).Figure 7Knockout of *GSE1*, but not *KDM3B*, in Gorlin 1 NES Cells Accelerates Tumorigenesis(A) Western blot showing loss of expression of *GSE1* (top) and KDM3B (bottom) in response to CRISPR/Cas9 knockout.(B) EdU assay of Gorlin 1 NES cells with control (Ctrl), *GSE1*, or *KDM3B* sgRNA. Data are presented as mean ± SEM.(C) CyQuant Direct cell proliferation assay of Gorlin 1 NES cells with Ctrl, *GSE1* or *KDM3B* sgRNA. Data are presented as mean ± SEM.(D) Kaplan-Meier curve showing reduced survival of mice injected with Gorlin 1 NES cells harboring *GSE1* sgRNA compared with Ctrl sgRNA or *KDM3B* sgRNA (n = 5). p = 0.0032 (log-rank test).(E) PCA (left) and SVM (right) classification showing three *GSE1*^−/−^ tumors subgrouped with SHH medulloblastoma.(F and G) *GSE1*^−/−^ cell lines were transduced with empty vector or the silent mutant *GSE1* (*GSE1*^*WT*^). Both cell lines were (F) analyzed by western blot analysis and (G) injected into mice (n = 5). p = 0.0031 (log-rank test).See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc4){ref-type="supplementary-material"}.

To exclude the possibility that accelerated tumorigenesis could have resulted as an off-target effect, we re-expressed wild-type GSE1 (referred as *GSE1*^*WT*^) to determine whether shortened latency could be rescued. We first generated cell lines from the *GSE1*^−/−^ tumors. Since these cell lines had stable expression of Cas9 and sgRNA targeting *GSE1*, we generated a plasmid of *GSE1*^*WT*^ containing silent mutations at the sgRNA binding site ([Figure S6](#mmc1){ref-type="supplementary-material"}E). *GSE1*^−/−^ cells were transduced with the *GSE1*^*WT*^ construct with silent mutations or with empty vector. Rescue of GSE1 expression was confirmed via western blot ([Figure 7](#fig7){ref-type="fig"}F). Empty vector (*GSE1*^−/−^) cells generated tumors between 60 and 63 days post-implantation, whereas re-expressed *GSE1*^*WT*^ cell lines generated tumors between 67 and 131 days post-transplant, suggesting GSE1 acts as a tumor suppressor ([Figure 7](#fig7){ref-type="fig"}G). From these analyses, we conclude that mutant *DDX3X* and loss of *GSE1* act as drivers of SHH medulloblastoma tumorigenesis, while mutations in *KDM3B* may represent a passenger.

Genomic Analysis of NES Cell-Derived Tumors {#sec2.7}
-------------------------------------------

We next performed the comparative genomic hybridization array (CGH) and whole exome sequencing (WES; 100× coverage) to identify copy number changes and mutations in WTC10 *MYCN* and Gorlin 1 tumors that may have been acquired *in vitro* or *in vivo*. At the chromosomal level, both sets of tumors lack copy number changes observed by array CGH ([Figure S7](#mmc1){ref-type="supplementary-material"}). At the base pair level, the overall mutation rates were quite low. Each of the three WTC10 *MYCN* tumors had 0 mutations per megabase, and the four Gorlin 1 tumors showed 0.6, 6.7, 0.5, and 16 mutations per megabase ([Tables S4](#mmc5){ref-type="supplementary-material"} and [S5](#mmc6){ref-type="supplementary-material"}), suggesting the mutant NES cells did not require additional mutations to generate tumors. We then investigated the mutation status of *PTCH1* and *TP53*, as both genes are frequently mutated in SHH medulloblastoma ([@bib7], [@bib44], [@bib64]), and dominant-negative mutations of *TP53* are known to be acquired *in vitro* in human pluripotent stem cells ([@bib60]). Interestingly, we identified a SNP at a coding exon in *TP53* (rs1042522, P72R) in both WTC10 *MYCN* tumors and Gorlin 1 tumors ([Tables S4](#mmc5){ref-type="supplementary-material"} and [S5](#mmc6){ref-type="supplementary-material"}). This SNP is unlikely to act as a dominant negative, as (1) it is located outside of the DNA-binding domain, where most dominant-negative p53 mutations occur ([@bib69]); (2) p53 was not detected by immunohistochemistry (IHC) in WTC10 *MYCN* tumors ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C); and (3) control WTC10 NES cells did not generate tumors ([Figure 1](#fig1){ref-type="fig"}C). We confirmed rs1042522 was present in the parental WTC10 NES cells by WES and the original iPSC by Sanger sequencing ([Table S6](#mmc7){ref-type="supplementary-material"}; data not shown) and thus was not acquired during differentiation to NES cells or upon implantation in mice. The SNP is not considered damaging according to the International Agency for Research on Cancer TP53 database (<http://p53.iarc.fr>) and is predicted to be benign by ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>). The minor allele frequency for rs1042522 ranges from 54% to 66% in multiple databases ([Table S6](#mmc7){ref-type="supplementary-material"}).

As expected, WES revealed the insertion mutation at *PTCH1* in the Gorlin 1 tumors leading to a premature STOP codon ([Table S7](#mmc8){ref-type="supplementary-material"}). In addition, a frameshift deletion in *PTCH2* was identified at exon 15, likely explaining the reduced expression levels and at least a contribution to the higher tumor penetrance compared to Gorlin 2 NES cells ([Tables S2](#mmc3){ref-type="supplementary-material"} and [S7](#mmc8){ref-type="supplementary-material"}).

A previous report by Zindy and collaborators ([@bib99]) showed that SHH medulloblastoma induced by enforced expression of *N-Myc* in mouse GNP cells sustained loss of *Ptch1*. To address whether human WTC10 *MYCN* tumors similarly showed loss of *PTCH1*, we analyzed WTC10 *MYCN* tumors, identifying a SNP in a coding exon of *PTCH1* (rs357564, P1315L) ([Table S4](#mmc5){ref-type="supplementary-material"}). This SNP was also detected in the original parental WTC10 NES cells by WES ([Table S6](#mmc7){ref-type="supplementary-material"}) and in iPSCs by Sanger sequencing (data not shown). ClinVar lists rs357564 as benign, and minor allele frequencies range from 30%--40% of populations surveyed in similar databases described for the *TP53* SNP. Since both the *PTCH1* SNP and the *TP53* SNP did not produce a tumor in our empty vector WTC10 NES cells ([Figure 1](#fig1){ref-type="fig"}C), both occur at high frequencies in the general population, and (for *TP53*) the SNP is located outside the hotspot region for dominant-negative mutations, neither is likely to affect tumorigenesis. Thus, our analysis suggests the mutations we introduced into NES cells represent the major drivers of diseases observed.

Discussion {#sec3}
==========

Pediatric embryonal cancers may occur when progenitors harbor mutations that cause deviation in their normal developmental program ([@bib65]). GEMMs have provided support for this model but show clear differences with human tumor phenotypes. Here, we demonstrate that defined genetic perturbations in a specific class of human progenitor cells lead to the formation of a distinct human cancer phenotype.

Medulloblastoma is among the best characterized of all cancers genetically. While the overall 5-year survival rate for medulloblastoma is 80% ([@bib16]), standard of care treatment with intracranial surgery, radiation, and intensive chemotherapy significantly impacts cognition and growth. Tumors can be divided into four main molecular subgroups (SHH, WNT, group 3, and group 4), although further genetic heterogeneity exists within each group ([@bib7], [@bib64]). Germline mutation in *PTCH1* predisposes patients to medulloblastoma, with mutation in *PTCH1* also occurring commonly in sporadic disease. In a recent clinical trial to treat mutant *PTCH1* tumors using the SMO inhibitor vismodegib, tumors showed regression initially but eventually relapsed ([@bib76]). Moreover, no targeted treatments exist for children with *MYCN*-amplified SHH tumors, a highly lethal subtype. Our findings establish two human stem cell-based genetic models of SHH medulloblastoma that could be used as tools for genetic screening or drug discovery for targeted therapies.

Misexpression of *MYCN* in human NES cells transplanted orthotopically in mice generated medulloblastoma *in vivo*. Amplification of *MYCN* is normally found in SHH or group 4 medulloblastoma and rarely in group 3 tumors ([@bib64]). Consistent with these associations, transcriptome analysis of human WTC10 *MYCN* tumors from NES cells aligned closest to SHH medulloblastoma. In contrast, the GTML model, our previously characterized GEMM for medulloblastoma also driven by *MYCN,* more closely resembled group 3 medulloblastoma ([Figures 2](#fig2){ref-type="fig"}C and 2D), a subgroup of medulloblastoma associated more commonly with amplification of *CMYC*. Furthermore, while GTML tumors showed much fewer regions of hypermethylation than human medulloblastoma patient tumors ([@bib14]), the human WTC10 *MYCN* tumors exhibited DMRs at almost half the sites found in patient-derived tumors ([Figure 2](#fig2){ref-type="fig"}A). Thus, the human WTC10 *MYCN* tumor model of medulloblastoma recapitulates the specific tumor subtype and epigenetic profile more accurately than the *MYCN* GEMM.

We then derived iPSCs from patients with Gorlin syndrome and differentiated them to NES cells. We showed that Gorlin NES cells recapitulated medulloblastoma predisposition and generated tumors following orthotropic transplantation. This model was leveraged to test candidate cooperating factors found in SHH tumors with somatic mutations in *PTCH1*. Missense mutation in the RNA helicase *DDX3X* and loss of *GSE1* both cooperated with *PTCH1* heterozygosity to drive tumorigenesis, whereas loss of candidate driver *KDM3B* did not ([Figures 6](#fig6){ref-type="fig"}D and [7](#fig7){ref-type="fig"}D). Thus, we have generated two genetically distinct models for medulloblastoma using a human stem cell system, exemplified functional evaluation of candidate cooperating genes in tumor initiation, and describe new experimental resources for the dissection of cooperative events in human medulloblastoma tumorigenesis.

Interestingly, chromosome copy number and single nucleotide variation analysis of tumors derived from human NES cells revealed few additional mutations compared to NES cells grown *in vitro* ([Figure S7](#mmc1){ref-type="supplementary-material"}; [Tables S4](#mmc5){ref-type="supplementary-material"} and [S5](#mmc6){ref-type="supplementary-material"}). The low mutation rate suggests the specific genetic manipulations we introduced into the NES cells were sufficient to drive tumorigenesis. Although both *MYC* and *PTCH1*^*+*/−^ usually require additional genetic mutations for transformation, NES cells are a stable and highly proliferative cell population ([@bib43]), and thus, the genes responsible for self-renewal could conceivably sensitize NES cells to transform from only a single genetic event. In contrast, mouse models of MYCN-driven medulloblastoma targeting progenitors of NES cells exhibited copy number alterations at the chromosomal level that likely cooperated with MYCN to generate tumors ([@bib85], [@bib99]). Although a previous study found a population of Nestin-expressing progenitors (NEPs) in mice to be more genomically unstable than GNPs, these NEPs are a quiescent population and less proliferative than GNPs ([@bib51]).

Both NES cells and neural stem cells (NSCs) are multipotent and have the capacity to generate neurons, astrocytes, and oligodendrocytes. However, NES cells have a significantly stronger tendency to differentiate toward neurons ([@bib43]). This bias toward neuronal lineages may explain why transformed NES cells (both Gorlin and MYCN driven) resemble medulloblastoma more than other brain tumor types thought to be derived from glial lineages such as glioblastoma, ependymoma, and pilocytic astrocytoma ([Figures 2](#fig2){ref-type="fig"}B, [S2](#mmc1){ref-type="supplementary-material"}B, [4](#fig4){ref-type="fig"}D, and [S4](#mmc1){ref-type="supplementary-material"}A). Similarly, the NEPs described by Li et al. are also more likely to differentiate toward neurons, and knockout of *Ptch1* in NEPs generated tumors resembling medulloblastoma ([@bib51]). Thus, a human stem cell-based model of a glial-derived brain tumor would likely require a cell type other than NES cells.

In addition to the association between Gorlin syndrome and SHH medulloblastoma, other medulloblastoma subtypes are also known to develop through genetic predisposition. Patients with Turcot's syndrome, who have a germline mutation in the adenomatous polyposis of the colon (*APC*) gene ([@bib26]), are predisposed to WNT-subtype medulloblastoma, which has a more indolent clinical course than SHH-subtype medulloblastoma ([@bib65]). While it will be of interest to model the precursors of WNT-subtype medulloblastoma via iPSCs derived from individuals with Turcot's syndrome, studies in mice suggest the molecular and clinical differences between medulloblastoma subtypes may be due to different developmental cells of origin in distinct regions of the cerebellum (lower rhombic lip for WNT, external germinal layer \[EGL\] for SHH, ventricular zone or EGL for group 3, and upper rhombic lip or nuclear transitory zone for group 4; [@bib4], [@bib21], [@bib39], [@bib54], [@bib68], [@bib77], [@bib97]). Thus, the transcriptome of these various cell types may provide the appropriate environment for specific mutations to transform the cells to medulloblastoma and would explain why some mutations are specific to a particular subgroup.

These divergent subpopulations of hindbrain cells could be generated from iPSCs or NES cells that express gene-specific reporter proteins to further investigate the influence of cellular origin on human medulloblastoma phenotype. Comparing isogenic lines that model distinct cells of origin could address whether mutations occur early at the NES cell stage to direct differentiation down a particular cell lineage or whether mutations occur after NES cells differentiated to the appropriate cell type. Although our study showed the NES cells can generate SHH medulloblastoma, these cells were not primed to generate GNP cells, as the transcriptomes were quite distinct and spontaneous differentiation of NES cells does not lead to maximal expression of the GNP marker *ATOH1* ([Figures 5](#fig5){ref-type="fig"}A and 5B). Instead, NES cells are prone to generating neurons of different lineages and have the capacity to generate GNPs.

The modeling of different medulloblastoma subtypes will have important implications for future targeted therapy. Xenograft models of human medulloblastoma in mice could be tested with specific genetic or drug therapies developed through screening of predisposed or transformed stem cells. In addition, the recapitulation of human medulloblastoma *in vitro* and *in vivo* could lead to methods for halting progression of premalignant cells. These strategies may help to prevent the progression of tumors in children and obviate the need for adjuvant chemotherapy or radiotherapy with the associated harmful side effects.

In conclusion, we demonstrate that human NES cells with genetic tumor predisposition generate bona fide medulloblastoma. Using known drivers of disease (*PTCH1* and *MYCN*), we demonstrate robust generation of SHH-subtype medulloblastoma and cooperativity between heterozygosity for *PTCH1* with mutations in *DDX3X* or *GSE1*. Thus, human NES cell-based models offer a powerful system for refined analyses of human medulloblastoma tumorigenesis, with the prospect of future applications in screening candidate therapeutic compounds.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**FLAGSigmaCat\# F1804, RRID:[AB_262044](nif-antibody:AB_262044){#intref0020}MYCNSanta Cruz BiotechnologyCat\# sc-53993, RRID:[AB_831602](nif-antibody:AB_831602){#intref0025}GAPDHMilliporeCat\# CB1001, RRID:[AB_2107426](nif-antibody:AB_2107426){#intref0030}SYNAPTOPHYSINThermo Fisher ScientificMA5-14532, RRID:[AB_10983675](nif-antibody:AB_10983675){#intref0035}P53AgilentCat\# M7001, RRID:[AB_2206626](nif-antibody:AB_2206626){#intref0040}NESTINR&D systemsCat\# MAB1259, RRID:[AB_2251304](nif-antibody:AB_2251304){#intref0045}SOX1R&D systemsCat\# AF3369, RRID:[AB_2239879](nif-antibody:AB_2239879){#intref0050}SOX2R&D systemsCat\# MAB2018, RRID:[AB_358009](nif-antibody:AB_358009){#intref0055}PAX6Proteintech Group12323-1-AP, RRID:[AB_2159695](nif-antibody:AB_2159695){#intref0060}OCT4Santa Cruz BIotechnologyCat\# sc-5279, RRID:[AB_628051](nif-antibody:AB_628051){#intref0065}NANOGR&D systemsCat\# AF1997, RRID:[AB_355097](nif-antibody:AB_355097){#intref0070}TUJ1R&D systemsCat\# MAB1195, RRID:[AB_357520](nif-antibody:AB_357520){#intref0075}TBRAR&D systemsCat\# AF2085, RRID:[AB_2200235](nif-antibody:AB_2200235){#intref0080}SOX17R&D systemsCat\# AF1924, RRID:[AB_35506](nif-antibody:AB_35506){#intref0085}GSE1ProteintechCat\# 24947-1-APKDM3BCell Signaling TechnologyCat\# 3100, RRID:[AB_1264192](nif-antibody:AB_1264192){#intref0090}Donkey anti-mouse Alexa Fluor 488Thermo Fisher ScientificCat\# A-21202Donkey anti-rabbit Alexa Fluor 647Thermo Fisher ScientificCat \# A-31573Donkey anti-goat Alexa Fluor 647Thermo Fisher ScientificCat\# A32849**Chemicals, Peptides, and Recombinant Proteins**mTeSR1StemCell Technologies, Inc.Cat\# 85850GelTrexThermo Fisher ScientificCat\# A1413202DMEM/F-12 + GlutamaxThermo Fisher ScientificCat\# ([@bib87])N-2 SupplementThermo Fisher ScientificCat\# 17502048B27 supplement w/o Vitamin AThermo Fisher ScientificCat\# 12587010Knockout DMEM/F-12Thermo Fisher ScientificCat\# 12660012GlucoseThermo Fisher ScientificCat\# A2494001Neurobasal-A mediumThermo Fisher ScientificCat\# A2477501Knockout serum replacementThermo Fisher ScientificCat\# 1[0828028]{.ul}2-MercaptoethanolThermo Fisher ScientificCat\# 31350010DPBS (without calcium/magnesium)Thermo Fisher ScientificCat\#14190-144DPBS (with calcium/magnesium)Thermo Fisher ScientificCat\#1[4040-133]{.ul}AccutaseInnovative Cell TechnologiesCat\# AT-104ThiazovivinStemcell technologiesCat\# 72254SB431542StemRDCat\# SB-050LDN-193189StemgentCat\# 04-0074LamininSigma AldrichCat\# L2020Poly-l-ornithine hydrobromideSigma AldrichCat\# P3655bFGFPeprotechCat\# 100-18BEGFPeprotechCat\# 100-15TrypLE ExpressThermo Fisher ScientificCat\# 1[2604013]{.ul}GlutamaxThermo Fisher Scientific*Cat\# 35050061*Trypsin-EDTAThermo Fisher Scientific*Cat\# 25300054*Collagenase, Type IVThermo Fisher ScientificCat\#17104019DMEMThermo Fisher ScientificCat\# 11965-092FBSSeradigmCat\# 1500-500ViralBoostAlstemCat\# VB100Lentivirus Precipitation SolutionAlstemCat\# VC100TransIT-LentiMirus BioCat\# 6603SHH (C-24II)GenScriptCat\# Z03067Wnt3aR&D systemsCat\# 5036-WNGDF7R&D systemsCat\# 8386-G7DAPIThermo Fisher ScientificCat\# D1306BMP7R&D SystemsCat\#354-BPEpiLife Medium with 60uM CalciumThermo Fisher ScientificCat \# M-EPI-500-CAEpiLife Defined Growth Supplement (EDGS)Thermo Fisher ScientificCat \# S-012-5Recombinant human collagen type 1 Coating Matrix kitThermo Fisher ScientificCat\# R-011-KAccuprime HiFiThermo Fisher Scientific*Cat\# 12346094*PuromycinSigma AldrichCat\# P9620GelRedBiotiumCat\# 41002Vilo SuperscriptThermo Fisher Scientific*Cat\# 11755050*SYBRKAPA BiosystemsCat\# KK4600**Critical Commercial Assays**Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay kitThermo Fisher ScientificCat \# C[10424]{.ul}Cyquant Direct Cell Proliferation AssayThermo Fisher ScientificCat\# C[35011]{.ul}AllPrep DNA/RNA Mini KitQIAGENCat\# 80204Surveyor mutation detection kitIntegrated DNA TechnologiesCat\# 706020Quick DNA miniprep kitZymo researchCat\# D3024Quick RNA miniprep kitZymo researchCat \#R1054Agilent RNA 6000 Nano kitAgilentCat\# 5067-1511**Deposited Data**Mouse granule neural precursor transcriptome data<https://www.ncbi.nlm.nih.gov/pubmed/30220501>ENA: PRJEB23051Raw RNaseqThis paperEGAS00001003620Raw Whole Exome SequencingThis paperEGAS00001003620Raw amplicon sequencingThis paperEGAS00001003620GTML tumor RNA expression data<https://www.ncbi.nlm.nih.gov/pubmed/22624711>GEO: [GSE36594](ncbi-geo:GSE36594){#intref0100}Human brain tumor expression data<https://www.ncbi.nlm.nih.gov/pubmed/24078694>GEO: [GSE50161](ncbi-geo:GSE50161){#intref0110}Human medulloblastoma tumor subgroup expression data<https://www.ncbi.nlm.nih.gov/pubmed/28609654>GEO: [GSE85217](ncbi-geo:GSE85217){#intref0120}**Experimental Models: Cell Lines**WTC10 iPSCConklin Lab<https://www.ncbi.nlm.nih.gov/pubmed/27794120>Gorlin 1 iPSCThis paperN/AGorlin 2 iPSCThis paperN/AWTC10 NES cellsThis paperN/AControl NES cellsThis paperN/AGorlin 1 NES cellsThis paperN/AGorlin 2 NES cellsThis paperN/ASai2 NES cellsSmith Lab<https://www.ncbi.nlm.nih.gov/pubmed/23884946>**Oligonucleotides**GSE1 sgRNA (TTGGAGCGATGGTCACCACG)Integrated DNA TechnologiesN/AKDM3B sgRNA (GCAGAACTGGTCCCCAACAT)Integrated DNA TechnologiesN/AGSE1 surveyor F (ctgcacgtggctgtcact);\
GSE1 surveyor R (actcaacctcgaaagctcca)Integrated DNA TechnologiesN/AKDM3B surveyor F (gctcctgcgatttaccatgt);\
KDM3B surveyor R (ccccaatcttcccgttaagt)Integrated DNA TechnologiesN/AGLi1 qPCR F (cagggaggaaagcagactga);\
GLI1 qPCR R (Actgctgcaggatgactgg)Integrated DNA TechnologiesN/AGAPDH qPCR F (CCATGGGGAAGGTGAAGGTC);\
GAPDH qPCR R (TGAAGGGGTCATTGATGGCA)Integrated DNA TechnologiesN/A**Recombinant DNA (plasmids)**pLentiCRISPR v2AddgeneRRID:Addgene_52961pCDH-CAG-3xFLAG-MYCN-mScarlet-LuciferaseThis paperN/ApCDH-CAG-mScarlet-LuciferaseThis paperN/ApCDH-CAG-3xFLAG-DDX3X (WT)-EF1a-Luciferase-BlastThis paperN/ApCDH-CAG-3xFLAG-DDX3X (R534S)-EF1a-Luciferase-BlastThis paperN/ApCDH-CAG-3xFLAG-DDX3X (R351W)-EF1a-Luciferase-BlastThis paperN/ApCDH-CAG-3xFLAG-DDX3X (R534S)-EF1a-Luciferase-BlastThis paperN/ApCDH-CAG-GSE1 (silent mut)-EF1a- BlastThis paperN/A**Software and Algorithms**Chip Analysis Methylation Pipeline (ChAMP v. 2.6.4)[@bib62]<https://bioconductor.org/packages/release/bioc/html/ChAMP.html>Metilene (v. 0.26)[@bib37]<https://www.bioinf.uni-leipzig.de/Software/metilene/>Samtools[@bib50]<http://samtools.sourceforge.net/>Burrows-Wheeler Aligner[@bib51]<http://bio-bwa.sourceforge.net/>Picard toolsBroad Institute<https://broadinstitute.github.io/picard/>Mutect2 (GATK4)[@bib58], [@bib13], [@bib73]<https://github.com/broadinstitute/gatk/>Varscan2[@bib41], [@bib42].<http://varscan.sourceforge.net/>Annovar[@bib92]<http://annovar.openbioinformatics.org/en/latest/>dbSNP[@bib79]<https://www.ncbi.nlm.nih.gov/snp/>Exome Aggregation Consortium (ExAC)[@bib48]<http://exac.broadinstitute.org/>Exome Sequencing Project (ESP)NHLBI Exome sequencing project, 2019<https://evs.gs.washington.edu/EVS/>1000 Genomes Project[@bib1]<http://www.internationalgenome.org/>STAR[@bib15]<https://github.com/alexdobin/STAR>DESeq[@bib56]<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>Conumee[@bib31]<https://www.bioconductor.org/packages/release/bioc/html/conumee.html>Bowtie2[@bib46]<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>Script for Metagene projection[@bib88]<https://www.ncbi.nlm.nih.gov/pubmed/17389406>Subread (v 1.5.2)[@bib52]<http://subread.sourceforge.net/>biomaRt (v 2.34.2)[@bib17]<http://bioconductor.org/packages/release/bioc/html/biomaRt.html>Other

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Dr. William A. Weiss (<waweiss@gmail.com>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Animals {#sec4.3.1}

Immunocompromised (NOD-scid IL2Rgamma^null^ or NSG) 6-8 week old female mice used for transplantation were purchased from Jackson Labs. Mice were maintained in the Animal Facility at UCSF. All experiments were performed in accordance with national guidelines and regulations, and with the approval of the IACUC at UCSF. 300,000 cells in 5uL of NES cell medium were injected per mouse. Injections were performed using a stereotactic machine starting from lambda 2mm right, 2mm down and 2mm deep. Mice were euthanized at endpoint, which was either signs of tumor growth (e.g., hunched back, weight loss, head tilt, etc) or 1 year post transplantation.

### iPSC culture {#sec4.3.2}

Male WTC10 iPSC ([@bib27]) were maintained on GelTrex coated 6-well plates in mTeSR1 media in a humidified 37°C incubator with 5% CO~2~. Cells were passaged every 4-5 days using Accutase and plated at 200-300,000 cells/well of a 6-well plate in 2mL mTeSR1 with 2uM of Thiazovivin. The Gorlin iPSC (male Gorlin 1 derived from KAS537 keratinocytes, female Gorlin 2 derived from KAS573 keratinocytes) and female control (derived from KTM1 keratinocytes) were maintained on MEF feeders in KSR medium (DMEM/F12, knockout serum replacement (KSR) 20%, L-glutamine 2mM, NEAA (0.1mM), 2-mercaptoethanol (0.1mM) supplemented with FGF2 (10ng/ml). The iPSC colonies were passaged 1:3 every 4-5 days using dissociation buffer (1mM calcium chloride, 0.025% trypsin, 1mg/ml collagenase IV, 1:5 KSR media, made in PBS solution). Gorlin iPSC were authenticated by Sanger sequencing of genomic DNA for *PTCH1* at c.G1762 (Gorlin 1) and c.C1925 (Gorlin 2). All experiments using iPSC in the William A Weiss lab (UCSF) were approved by Human Gamete, Embryo and Stem Cell Research Committee of the UCSF Stem Cell Research Oversight Committee. All experiments using iPSC in the Austin Smith lab (University of Cambridge) were performed under ethical approval from the Cambridgeshire Research Ethics Committee (Reference 96/085). The storage and use of human tissue was approved by the Human Tissue Authority, UK (License number 12196). Although we observed a difference in tumorigenic penetrance using a male (Gorlin 1) and female (Gorlin 2) NES cells ([Figure 4](#fig4){ref-type="fig"}B), this is likely due to differences in transcriptomes unrelated to the sex identity.

Method Details {#sec4.4}
--------------

### Gorlin iPSC derivation {#sec4.4.1}

Gorlin (KAS537, KAS573) and normal human keratinocytes (KTM1) were obtained from patients and healthy controls respectively as previously described ([@bib31], [@bib82]). Primary human adult keratinocytes obtained from Thierry Magnaldo's laboratory were cultured in recombinant human collagen type I- plated tissue culture flasks in EpiLife Medium supplemented with EpiLife Defined Growth Supplement (EDGS). Transgene-free reprogramming of keratinocytes to iPSC was achieved using Sendai virus (SeV), a negative sense single-stranded RNA virus that replicates in the cytoplasm without a DNA phase ([@bib19]). In brief, approximately 5 × 10^4^ to 10 × 10^4^ keratinocytes were seeded per well of a six well plate in EpiLife media supplemented with EDGS. Each well was then infected with separate SeV constructs carrying the pluripotency genes Oct4, Klf4, Sox2 and c-Myc at a multiplicity of infection (MOI) of 5 for 24 hours in 1ml EpiLife media per well. Virus containing media was removed and the cells were washed gently twice with PBS and replaced with fresh Epilife media. On day 4 post-infection, keratinocytes were collected, counted and seeded at a density of 4 × 10^5^ initially in EpiLife media on inactivated MEFs. Epilife media was replaced with KSR medium supplemented with FGF2 (10ng/ml) after a further 24 hours. KSR/FGF2 media was changed every two days and pluripotent stem cell colonies emerged after 4-6 weeks. Keratinocyte derived iPSC were picked and expanded on MEF feeders in KSR/FGF2 media. Informed consent was obtained from all subjects.

### Teratoma formation assay {#sec4.4.2}

Human iPSC were injected into the kidney capsule of NOD/SKID mice using a protocol adapted from ([@bib62]). Mice were sacrificed after 3 months, or when the mice developed a visible abdominal mass. The teratomas were fixed with 10% formalin and prepared for paraffin embedded sections.

### Embryoid body formation and differentiation {#sec4.4.3}

iPSC colonies were floated in KSR media (without FGF2) on untreated tissue culture plates at 37 degrees for 1-2 weeks. The embryoid bodies were then plated on tissue culture flasks coated with poly-L-ornithine and laminin in N2B27 media (1:1 Neurobasal:DMEM/F12, L-glutamine 2mM, N-2 supplement 0.5x, B27 w/o vitamin A supplement 0.5x, 2-mercaptoethanol (0.1mM)) for further 1-2 weeks.

### Differentiation to and maintenance of neuroepithelial stem (NES) cells {#sec4.4.4}

iPSC differentiation to NES cells was performed as previously described ([@bib43]). Briefly, iPSC were cultured as embryoid bodies in KSR medium with [SB431542](ccdc:SB431542){#intref0235} (10uM), [LDN193189](ncbi-p:LDN193189){#intref0240} (500nM) for 3 days, N2 medium (DMEM/F-12 (0.5x) & Neurobasal medium (0.5x), N2 supplement (0.5x), B27 supplement (0.5x)) for 6 days and plated on poly-L-ornithine/laminin coated plates for another 6 days in N2 medium. Rosettes were picked, dissociated in Accutase for 5 min at 37°C and plated on poly-L-ornithine/laminin coated wells in NES cell medium (DMEM/F-12, Glutamax, 1x N2 supplement, 0.05x B27 w/o vitamin A supplement, 1.6g/L Glucose, 10-20ng/mL EGF, 10-20ng/mL FGF2) in a humidified 37**°**C incubator with 5% CO~2~. NES cells were fed daily and passaged every 3-4 days using TrypLE Express and plated at 500-600,000 cells/well of a 6-well plate in 2mL NES cell medium.

### Spontaneous and direct differentiation of NES cells {#sec4.4.5}

NES cells were differentiated spontaneously or directly in [Figure 5](#fig5){ref-type="fig"}. For spontaneous differentiation, NES cells were cultured in N2 medium for 2 days. For direct differentiation, NES cells were grown in N2 medium supplemented with Wnt3a (20ng/mL) and GDF7 (100ng/mL) for 2 days.

### CRISPR plasmid and mutation detection {#sec4.4.6}

sgRNA targeting GSE1 and KDM3B were designed using <http://crispor.org> and cloned into pLentiCRISPR v2. After NES cells were transduced with plasmids encoding Cas9 and sgRNA, we selected the cell population with puromycin. Genomic DNA was extracted, and PCR was performed across the targeted junction using Accuprime HiFi Taq. Primers for sgRNA and PCR were obtained from IDT Technologies. PCR products were digested using Surveyor Nuclease mutation detection kit and visualized on 10% TBE gels stained in GelRed. To identify mutations and quantitate efficiency of mutations, amplicon sequencing was performed using services provided by GENEWIZ (<https://www.genewiz.com/en>).

### Karyotype analysis {#sec4.4.7}

G-band karyotype analysis of NES cells were analyzed by Cincinnati Children's Hospital (<https://www.cincinnatichildrens.org/service/d/diagnostic-labs/cytogenetics>),

### RT-qPCR {#sec4.4.8}

RNA was extracted using an RNA extraction kit (Zymo Research). 500ng of RNA was converted to cDNA using Vilo Superscript (Thermo Fisher) in a 20uL final volume and the following settings: 25**°**C for 10min, 42**°**C for 60 min and 85**°**C for 5 min. cDNA was then diluted in 80uL of water and qPCR was performed in a 384 well plate using SYBR green (KAPA Biosystems) on an AB7900HT machine with the following settings: 95**°**C for 1 min, 40 cycles (95**°**C for 3 s and 60**°**C for 1 min). Each qPCR reaction occurred in final volume of 10uL containing 5uL SYBR mastermix, 5uM of each forward and reverse primer, and 0.4uL of the cDNA. Gene expression was normalized to GAPDH and represented as fold increase over control cell lines.

### Cell proliferation assays {#sec4.4.9}

EdU and CyQuant Direct cell proliferation kits were used according to manufacturer protocol. For EdU assays, cells were treated with 10uM EdU for 1hours, fixed and undergone Click-iT chemistry to stain for EdU in cells. Subsequently, cells were counterstained in DAPI and run on BD FACSAria III to obtain the cell populations in G1, S and G2/M phase. For CyQuant Direct, cells were plated on 3-4 poly-l-ornithine/laminin coated 96 well plates at 20,000 cells per well. Each day, one plate was fixed and stained using the CyQuant Direct nucleic acid stain and background suppression dye and analyzed on a plate reader for green fluorescence in the nucleic acid stain. Raw data was normalized to Day 1 measurements to determine the percentage of increase in cells on subsequent days.

### RNA-seq {#sec4.4.10}

Total RNA was extracted from flash frozen tissue using a AllPrep DNA/RNA Mini Kit. Quality of total RNA samples was checked on an Agilent Bioanalyzer 2100 RNA Nano chip (Agilent). RNA samples with RNA Integrity Numbers of at least 7 were sent to Novogene (<https://en.novogene.com/>) for library preparation (polyA enrichment) and RNA sequencing (150 base pair Paired End reads, 50 million reads total).

### Differential gene expression analysis of NES cells and tumors derived from NES cells {#sec4.4.11}

To examine transcriptomic differences, cDNA reads were aligned to hg19 using STAR alignment(v2.6.1) to generate bam files ([@bib15]). Unnormalized gene read counts were generated using STAR. Differentially expressed genes were normalized and analyzed using the DESeq2(v1.22.1) package in R(v3.5.1) ([@bib56]).

### Comparison of transcriptomes of tumors from NES cells with different brain tumor types and medulloblastoma subgroups {#sec4.4.12}

Raw RNA-seq reads were mapped to the human genome assembly GRCh37/hg19 using STAR v2.5.3a. The alignment was performed with a two-pass approach, where splice junctions discovered during a first alignment guide the forming of a final second alignment. Finally, reads unmapped by STAR were subjected to a final round of alignment via bowtie2 2.3.4.3 ([@bib46]). Read counts for genes were extracted using the featureCounts function from the subread 1.5.2 package and utilizing h19 gene annotations from GENCODE ([@bib52]). Subsequently, read counts were converted to measures of transcripts per million (TPM). Ensembl gene ids were translated to official gene symbols (HUGO Gene Nomenclature Committee; HGNC) in R using the biomaRt package ([@bib17]).

### Microarray expression preprocessing {#sec4.4.13}

CEL files from three microarray expression datasets were downloaded from GEO: medulloblastoma samples with subgroup annotation (GEO: [GSE85217](ncbi-geo:GSE85217){#interref0305}, 763 samples, ([@bib7])), brain tumors & normal brain (GEO: [GSE50161](ncbi-geo:GSE50161){#interref0310}, 130 samples, ([@bib23])), GTML (GEO: [GSE36594](ncbi-geo:GSE36594){#interref0315}, 32 samples, ([@bib86])). CEL files were preprocessed with the Robust Multichip Average (RMA) protocol in the Affymetrix Expression Console (AEC). Gene symbols in the resulting gene expression matrix were translated to official HGNC gene symbols and multiple rows associated with the same gene symbol were collapsed using the average.

### Cross-dataset classifications {#sec4.4.14}

Tumor samples were classified and compared with other brain tumors or medulloblastoma subgroups in R using a package for cross-platform comparisons of transcriptional profiles ([@bib88]). Specifically, the script was employed using either the GEO: [GSE85217](ncbi-p:GSE85217){#intref0265} or GEO: [GSE50161](ncbi-p:GSE50161){#intref0270} as model and then projecting the gene expression data of tumor samples onto these model data, respectively. From the various outputs generated by the R package, we employed the hierarchical clustering plot, principal component analyses plot, and results of the support vector machine classification in order to characterize our tumor samples.

### Granular Neural Precursor (GNP) comparison {#sec4.4.15}

Raw single cell RNA-seq data of GNP cells from normal mouse cerebellum were obtained from ENA: PRJEB23051 ([@bib6]). Clusters 21 and 22 were found to be indicative of GNP cells and were subsequently compared to RNA-sequencing of our NES cells. Differentially expressed genes were analyzed using the DESeq2(v1.22.1) package in R(v3.5.1) ([@bib56]). To account for the coverage difference in single cell versus bulk RNA-sequencing, we elected to not filter for coverage in GNP expression comparisons.

### Whole Exome Sequencing (WES) and variant discovery {#sec4.4.16}

Genomic DNA was isolated from tumors and NES cells using AllPrep DNA/RNA Mini Kit. Quality of genomic DNA was checked on a 1% agarose gel. Exome capture, library preparation and whole exome sequencing (150 base pair Paired End reads at 100x coverage) was conducted using Agilent SureSelect Human All Exon V6 Kit by Novogene (<https://en.novogene.com/>).

To examine genomic variants, exome paired-end reads were aligned to hg19/grch37 using BWA-MEM(v0.7.15) and sorted using SAMtools to produced sorted-mapped bams ([@bib49], [@bib50]). The sorted-mapped bams were processed by marking duplicates and recalibrating bases using Picard tools(v2.18.25) (<http://broadinstitute.github.io/picard/>). Single nucleotide variants and indels (insertions and deletions) were called using Mutect2(v4.1) and Varscan2(v2.4.3) following best practices ([@bib13], [@bib42], [@bib41], [@bib58], [@bib73]). Somatic variants were called using NES cells as the normal sample and the transformed or implanted cells as the tumor sample. Tumor-only variants of each sample were also called in tumor-only mode. Somatic and tumor-only variants were annotated using annovar(v.2015) ([@bib92]). Population frequency of each variant was gathered from multiple databases ([@bib1], [@bib29], [@bib38], [@bib48], [@bib78], [@bib79]).

### Copy number variation analysis {#sec4.4.17}

DNA was extracted from tumors and analyzed for genome-wide DNA methylation patterns using the Illumina HumanMethylationEPIC BeadChip (850k) array. Processing of DNA methylation data was performed with custom approaches as previously described ([@bib31], [@bib82]), and copy number profiles were generated using the 'conumee' package for R (<https://www.bioconductor.org/packages/release/bioc/html/conumee.html>).

### Methylation array analysis {#sec4.4.18}

Raw methylation array data were processed, filtered, and normalized using the Chip Analysis Methylation Pipeline (ChAMP v. 2.6.4) ([@bib62]) within Bioconductor and in R (v. 3.3.3). Human cerebellum and human medulloblastoma tumors were processed separately using 450K methods whereas iPSC-based tumors used EPIC methods. Overlapping normalized beta values from probes that passed QC (n = 348,212) were combined from all groups. Differential methylation analysis was performed using metilene (v. 0.26)([@bib37]) with a minimum CpG length of 10, a minimum absolute difference of 0.1, and adjusted p values \< 0.05. Overlapping DMRs were identified using the GenomicRanges package (v 1.26.4).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Mutational rate estimates {#sec4.5.1}

The mutational rate of the NES cell tumors were determined by extracting the nonsynonymous, synonymous, stop modulating, somatic variants; these variants are further filtered by excluding variants found above 1% in population frequency databases ([@bib1], [@bib29], [@bib38], [@bib48], [@bib78], [@bib79]). Somatic variants were filtered for false positives by excluding variants with fewer than 10 reads and at a variant allele frequency of 15% or lower. The mutational rate was estimated by dividing the remaining somatic variants by the size of the exome (30 megabases).

### Quantitation of IHC for p53 and FLAG-MYCN {#sec4.5.2}

For quantitation of nuclear p53 and FLAG-MYCN staining in IHC, the number of positive cells was divided by the number of total cells. Positive and total cells were counted manually. A minimum of three fields of view were analyzed per tumor, with approximately 400 cells in each field of view. Data represent mean ± standard error of mean.

### Statistical analysis {#sec4.5.3}

For qPCR, EdU and CyQuant Direct Cell proliferation assays, data points represent the average of 3 independent experiments ± standard error of mean and p values were generated by one-tailed t test (unequal variance) For survival curves, p values were calculated by Log-rank (Mantel-Cox test) using GraphPad Prism. For all statistical analyses, p value less than 0.05 was interpreted as statistically significant.

Data and Code Availability {#sec4.6}
--------------------------

Raw data for whole exome sequencing, RNA-seq and amplicon sequencing are stored in the European Genome Archive (<https://ega-archive.org>). The accession number for the sequencing data reported in this paper is EGA: EGAS00001003620. Previously published datasets used are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}.
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